If you or a loved one has been taking Reglan and notice involuntary facial or limb movements, you may be concerned about tardive dyskinesia. Building on decades of clinical research, this page explains the key warning signs and diagnostic considerations for California patients.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. The FDA-approved labeling includes a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer treatment duration and higher cumulative doses. Reglan is contraindicated in patients with a history of TD, and the labeling instructs prescribers to use the drug for the shortest duration necessary and to reassess the need for continued treatment periodically (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD includes repetitive, involuntary movements such as lip smacking, grimacing, tongue protrusion, and rapid eye blinking. In some cases, movements affect the trunk or limbs, leading to gait disturbances or postural instability. Diagnosis is based on clinical examination and a history of exposure to dopamine-blocking agents like metoclopramide. The condition may be partially suppressed by continued use of the drug, which can delay recognition and worsen the prognosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Reglan is a dopamine D2 receptor antagonist. By blocking dopamine receptors in the striatum, it alters motor control pathways, leading to the abnormal involuntary movements seen in TD. The mechanism involves upregulation of dopamine receptors and oxidative stress in basal ganglia neurons, which may become irreversible after prolonged exposure. The boxed warning emphasizes that TD can occur even after short-term use, but the risk is highest with treatment exceeding 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the labeling advises avoiding treatment longer than 12 weeks; if longer use is unavoidable, routine monitoring for TD signs is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The adequacy of warnings regarding Reglan and TD has been a subject of litigation. The boxed warning was added to the label in 2009, but many patients were prescribed Reglan for extended periods before that update. The warning explicitly states that TD is a serious, potentially irreversible disorder and that Reglan should be discontinued immediately if signs or symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite this, some patients continued to receive the drug for months or years, often for off-label uses or without adequate monitoring. The FDA also notes that Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Settlement-related considerations for affected patients in California involve the statute of limitations, which generally requires filing a claim within a certain period after discovering the injury or after it should have been discovered. For TD, the timeline between exposure and documented harm can be variable. Some patients develop symptoms within weeks, while others may not notice movements until after years of use. The boxed warning notes that TD may be suppressed by continued metoclopramide use, potentially masking the condition until the drug is discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delay in diagnosis can complicate the determination of when the statute of limitations begins to run. In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For TD, the 'discovery rule' may apply, meaning the clock starts when the patient knew or reasonably should have known that Reglan caused their movement disorder. Given that TD can develop insidiously and may be misattributed to other causes, patients may not connect their symptoms to Reglan until years after exposure. Legal counsel can help assess individual circumstances, including the duration of Reglan use, the onset of symptoms, and the date of diagnosis.
The risk of TD is dose-dependent and cumulative. The labeling states that the maximum duration for gastroesophageal reflux treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who took Reglan for longer periods, especially those with diabetic gastroparesis who may have used it for months or years, face a higher risk. The boxed warning also notes that Reglan is contraindicated in patients with a history of TD, underscoring the importance of screening before prescribing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients considering a settlement, documentation of the duration of Reglan use, the presence of TD symptoms, and medical records confirming the diagnosis are critical. The FDA label provides clear evidence that the manufacturer was aware of the TD risk and that the drug should be used only for short periods. Failure to adhere to these warnings may form the basis of a claim. However, each case is fact-specific, and the statute of limitations in California requires prompt action after discovery of the injury.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For tardive dyskinesia caused by Reglan, the 'discovery rule' may apply, meaning the clock starts when the patient knew or reasonably should have known that Reglan caused their movement disorder. Because TD can develop insidiously and may be masked by continued use of the drug, patients may not discover the connection until years after exposure. It is crucial to consult with an attorney promptly to assess individual circumstances.
Key documentation includes medical records showing the duration and dosage of Reglan use, a confirmed diagnosis of tardive dyskinesia by a qualified physician, and records documenting the onset and progression of symptoms. Additionally, evidence that the prescribing physician failed to adhere to FDA warnings, such as using Reglan for longer than 12 weeks or without monitoring for TD, can strengthen a claim. The FDA label explicitly states that Reglan should be used for the shortest duration necessary and that TD can occur even after short-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.